Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs CB 1158 (Primary) ; Epacadostat (Primary) ; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 29 Oct 2018 Planned End Date changed from 17 Nov 2018 to 31 Jan 2019.
    • 26 Jun 2018 Planned End Date changed from 21 Feb 2021 to 17 Nov 2018.
    • 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top